SYK Activation Enhances Dendritic Cell Functions in Spontaneous Rheumatoid Arthritis Authors: Zhiyang Zeng, Xiya Cao, Haozhe Guo, Yuxuan Lai, Weihua Yang, Youyuan He, Jialiang Sun, Zhenliang Sun, Dali Li, Yamin Tan Published: 2025 ABSTRACT The pathogenesis of rheumatoid arthritis (RA) involves an aberrant number and/or activation of dendritic cells (DCs) within the synovial microenvironment. Targeting synovial DCs represents an attractive approach for the treatment of RA. Spleen tyrosine kinase (SYK), a pivotal molecule in immune cell receptor signaling pathways, is known to play a critical role in RA progression. However, the impact of SYK on DC biology under RA-specific pathological conditions remains incompletely understood. In this study, we employed a spontaneous RA mouse model carrying a gain-of-function SYK variant (SYKS544Y) to investigate the effects of SYK activation on DCs. Our findings demonstrate that SYK activation promotes the expansion of the DCs population (CD11C+MHCII+), particularly the CD11C+MHCII+CD11B+CD8a− subtype, in blood, spleen, and ankle. Furthermore, SYK activation enhances DC maturation and endocytosis by upregulating CD40 and CD86. Additionally, bone-marrow-derived DCs from SYKS544Y mice exhibit increased T-cell proliferative activity. Collectively, these results suggest that gain-of-function SYK may contribute to RA pathogenesis by promoting DC expansion and maturation, thereby modulating immune responses in the synovial environment.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10753-025-02405-2. Introduction Rheumatoid arthritis (RA) is an incurable autoimmune disease characterized by joint pain and swelling, bone erosion, and synovial hyperplasia [1]. Without timely and effective intervention, RA can progress to irreversible joint damage, disability, and even mortality [2]. The progression of RA typically involves infiltration of a large number of immune cells and higher numbers of dendritic cells (DCs), myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) were always found in the synovial fluid (SF) from RA patients [3]. These DCs migrate to the joint in response to chemokines or growth factors secreted by immune cells in SF [4, 5]. By exerting autoantigen presentation and proinflammatory effects, DCs in the synovium can profoundly influence RA progression. DCs possess an intrinsic capacity for cross-presentation via MHC class I to activate CD8 and CD4 T cells [6]. In RA patients, synovial DCs exhibit upregulated expression of MHC and costimulatory molecules, such as RelB [7], receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) [8], CD80, CD86, and CD40, and display enhanced T-cell proliferative capacity [9]. Furthermore, when stimulated ex vivo with immune complexes or TLR agonists, synovial DCs secrete increased levels of proinflammatory cytokines, such as tumor necrosis factor (TNF) [3], interleukin 1β (IL1β), IL6, and IL12 [10]. Although the role of DCs in RA pathogenesis has been extensively studied, the underlying mechanisms driving DC function in the synovial microenvironment remain unclear. Spleen tyrosine kinase (SYK) is a pivotal molecule in immune cell receptor signaling pathways, including B-cell receptors, T-cell receptors, and crystallizable fragment (Fc) receptors [11]. Upon antigen encounter or proinflammatory stimuli, SYK is rapidly recruited and phosphorylated by immune cell receptors via immunoreceptor tyrosine-based activation motifs (ITAMs). Phosphorylated SYK (p-SYK) then phosphorylates its direct binding partners, such as the regulatory subunits of phosphoinositide 3‑kinases (PI3Ks), phospholipase Cγ (PlCγ) isoforms, and the SH2 domain‑containing leukocyte protein (SLP). These binding proteins activate downstream signaling pathways, which eventually trigger various cellular responses, including differentiation, proliferation, cytokine release, and survival [12]. Given its diverse roles in immune cells, SYK is implicated in autoimmune diseases. Indeed, myeloid cell-specific Syk knockout mice and SYK-deficient bone marrow chimeras are protected from autoantibody-induced arthritis [13]. Importantly, SYK inhibition ameliorates disease not only in RA mouse models [14, 15] but also in RA patients [16–18]. Nevertheless, systemic SYK inhibition is limited by serious side effects, such as neutropenia and diarrhea, due to SYK’s broad expression profile. Consequently, no SYK inhibitor has been approved for RA treatment to date. Thus, identifying the critical immune cell types and functions influenced by SYK activation remains a priority. We recently identified a pathogenic gain-of-function variant in SYK (p.Ser550Tyr) that results in systemic inflammatory diseases, including spontaneous RA, and a mouse model harboring the SYK(p.Ser544Tyr) (hereafter denoted SYKS544Y) mutation developed RA at the age of two months, providing a valuable tool to study SYK activation-mediated cellular functional changes in RA pathogenesis [19]. In this study, by utilizing the gain-of-function SYKS544Y model, we uncovered a critical role of SYK in promoting DC expansion, maturation, and endocytosis. Furthermore, we reveal that SYK activation enhances T-cell proliferation in vivo. These findings suggest that SYK-mediated enhancement of DC functions may drive RA progression. Materials and Methods Animal Models SYKS544Y gain-of-function mouse models on a C57BL/6 background have been described previously [19]. Wild-type and OT-I mice on a C57BL/6 background were purchased from the Shanghai Laboratory Animal Center. All mice were housed in specific-pathogen-free (SPF) conditions. Animal experiments were conducted in accordance with the regulations of the Association of Assessment and Accreditation of the Laboratory Animal Care in Shanghai and were approved by the East China Normal University Center for Animal Research (Notification No. m20241002). Mice aged 12 to 15 weeks were used in all experiments. Histopathology and Immunohistochemistry Staining Tissues were fixed overnight in a 4℃ shaker with 4% paraformaldehyde (PFA), then embedded into paraffin blocks and cut into 4–6 mm slides. For histopathological analysis, slides were processed using hematoxylin and eosin (H&E) staining and visualized using an Olympus BX51 microscope. For immunohistochemistry staining, endogenous peroxidase activity was quenched with 3% H2O2 in methanol for 10 min and then washed with PBS. After antigen retrieval by boiling the slides in antigen retrieval buffer [10 mM Tris base, 1 mM EDTA (pH 9.0)], specimens were blocked with 3% goat serum and incubated with the primary antibody overnight at 4 °C. After incubation with the secondary antibody for 30 min, sections were developed with DAB reagent according to the manufacturer’s protocol (ABC kit, Vector Labs, PK4001) and counterstained with hematoxylin, dehydrated, and mounted in neutral resins before visualization using an Olympus BX51 microscope. Primary antibodies and their dilutions were as follows: CD11C (1:200, Cell Signaling Technology, #97585). Assessment of Arthritis Arthritis clinical scores were assessed in WT and SYKS544Y mice at the age of 3 months. The severity of arthritis was assessed in each mouse using an established semi-quantitative scoring system of 0–4 described previously [20]. Briefly, each limb was scored as follows: 0, normal, without any macroscopic signs of arthritis; 1, mild redness and swelling of the ankle, or apparent redness and swelling limited to individual digits, regardless of the number of affected digits; 2, moderate redness and swelling of the ankle; 3, redness and swelling of the entire paw, including digits; 4, maximally inflamed limb with involvement of multiple joints (maximum possible score 16). Flow Cytometry Analysis The method for obtaining single-cell suspension from blood, spleen, and ankle was described previously. Briefly, blood was collected, and red blood cells (RBCs) were depleted using RBC lysis buffer (BD Biosciences, 555899). Cells were then filtered through a 40-µm strainer, and resuspended in PBS with 1% FBS. The spleen was chopped into pieces and filtered through a 40-µm strainer, RBCs were depleted using RBC lysis buffer, and single cells were resuspended in wash buffer (1% FBS in PBS). Ankles were dissected and chopped into 2-mm pieces and incubated in 5 mL digestion buffer (2 mg mL− 1 Dispase II, Beyotime, 2 mg mL− 1collagenase IV, Sigma) for 90 min. The supernatant was passed through a 70-µm strainer and resuspended in PBS with 1% FBS. For flow cytometry, 1 million cells were stained with antibodies for 30 min at 4 °C, followed by three washes with wash buffer and centrifugation at 1,000 r.p.m. and 4 °C for 10 min. Finally, supernatants were discarded, and cells were resuspended in 300 µL wash buffer for analysis using an LSRFortessa and FlowJo v10.7.1 (BD). Primary fluorescent-labeled antibodies were purchased from BioLegend: anti-CD11C (BioLegend; N418; APC), anti-MHCII (BioLegend; M5/114.15.2; PE), anti-CD11B (BioLegend; M1/70; BV510; FITC), anti-CD3 (BioLegend; 17A2; PE-Cy7), anti-CD45 (BioLegend; 104; PerCP-Cy5.5 and FITC), anti-CD8a (BioLegend; 104; A700), anti-CD40 (BioLegend; 3/23; FITC), anti-CD86 (BioLegend; A17199A; PE-Cy7), Zombie Violet™ Fixable Viability Kit (BioLegend, 423114, BV421), anti-B220 (BioLegend; RA3-6B2; PE-Cy7), anti-CCR2 (BioLegend; 150627; PE-Cy7), anti-CD304 (BioLegend; 145212; APC). For intracellular staining, anti-pSYK (Tyr525/526) (Cell Signaling Technology, 4349 S), diluted in Perm/Wash Buffer (BD Biosciences), were applied to cells and allowed to incubate for 30 min. After the staining steps, cells were washed twice with Perm/Wash Buffer and once with FACS buffer. Finally, supernatants were discarded, and cells were resuspended in 300 µL wash buffer for analysis using an LSRFortessa and FlowJo v10.7.1 (BD). Micro-CT Ankle joints from WT and SYKS544Y mice were dissected, fixed in 4% PFA-PBS at 4℃ shaker in the dark overnight, washed with cold PBS for 3–5 times (15 min each), and then examined by high-resolution micro-CT (Skyscan1272). Three-dimensional reconstruction was then performed using NRecon software (v1.7.0.4), and the images were processed with CT-analyzer software (Bruker, v1.16.9.0). Bone Marrow-derived Dendritic Cell (BMDC) Culture Bone marrow cells were extracted from the femurs and tibias, dispersed to generate a single-cell suspension, and subjected to red blood cell lysis using RBC lysis buffer (BD Biosciences, 555899). Cells were seeded into 6-well plates at a density of 1 × 10⁶ cells/mL in RPMI 1640 medium (Gibco) supplemented with 10% FBS, 10 ng/mL recombinant murine IL-4 (Peprotech), and 20 ng/mL recombinant murine GM-CSF (Peprotech). The SYK inhibitor R406 was added to selected cultures once every other day to a final concentration of 2 µM. Cultures were maintained at 37 °C/5% CO₂. Fresh medium (1 mL) was added on days 3 and 6. Cells typically matured by days 7–8, exhibiting elevated CD11C surface expression. To induce terminal maturation, 1 µg/mL lipopolysaccharide (LPS; Sigma) was added on day 7 and incubated for 24 h. Mature BMDCs were then harvested for subsequent experiments. Western Blot Bone marrow-derived dendritic cells from WT and SYKS544Y mice were collected, and total protein content was released in lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, plus protease inhibitor cocktail and phosphatase inhibitor cocktail). Cell lysates were then subjected to 10% SDS–polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 5% bovine serum albumin (BSA, Sangon Biotech) for 1 h at room temperature and probed overnight at 4 °C with antibodies specific for pSyk (Tyr525/526) (Cell Signaling Technology, 13198), Syk (Cell Signaling Technology, 2710), pErk1/2 (T202/Y204) (Cell Signaling Technology, 9201), Total Erk1/2 (Cell Signaling Technology, 4695), pJnk (T183/Y185) (Cell Signaling Technology, 4668), Total Jnk (Cell Signaling Technology, 4219), pSTAT3(Tyr705) (Cell Signaling Technology, 4489), STAT3 (Cell Signaling Technology, 12640), β-actin (Sigma, A5316), followed by incubation for 1 h at room temperature with secondary (anti-mouse IR-Dye 800CW, LI-COR; anti-rabbit IR‐Dye 680RD, LIC-OR) antibodies. An Odyssey imager (Li‐COR) was used to visualize labeled immunoblots. FITC–Dextran Uptake Assay The endocytic capacity of mature (treated with LPS) and immature DCs was evaluated using an FITC–dextran uptake assay. Cells were pre-incubated for 45 min at 37 °C or on ice (4 °C; negative control). Subsequently, they were incubated with FITC-conjugated dextran (1 mg/mL; Sigma-Aldrich) in culture medium for 1 h at 37 °C or 4 °C. Following incubation, cells were washed twice with ice-cold PBS containing 1% bovine serum albumin (BSA) and analyzed immediately by flow cytometry (LSRFortessa; BD Biosciences). Cells exhibiting positive FITC fluorescence were considered to have internalized dextran. MTS Assay for DC Proliferation The Cell Titer 96 Aqueous One Solution Reagent (Gibico) was used to evaluate proliferation. Both WT and SYKS544Y DCs were seeded in 96-well plates at 5 × 10³ cells per well in complete RPMI 1640 medium. After incubation at 37 °C with 5% CO₂ for 24 and 48 h, 20 µL of MTS reagent (Gibico) was added to each well, followed by an additional 2 h incubation under the same conditions. Absorbance was measured at 490 nm using a microplate reader (Bio-Rad). The proliferation rate was determined by comparing the absorbance of treated wells to that of control wells. In Vitro Cross-presentation Assay CD8+ T cells were isolated from single-cell suspensions of spleens of OT-I mice using anti-CD8 microbeads (BioLegend) according to the manufacturer’s protocol. The isolated T cells were stained with CFSE Cell Division Tracking Kit (BioLegend) before plating in complete RPMI in round-bottom 96-well plates (3 × 105 cells/well). For antigen loading, mature DCs were incubated with 1 µg/mL OVA₂₅₇–₂₆₄ peptide (SIINFEKL; Sigma) for 1 h at 37 °C. Subsequently, 1 × 10⁵ peptide-pulsed DCs were seeded into 24-well plates and co-cultured with CFSE-labeled OT-1 CD8⁺ T cells at T: DC cell ratios of 5:1, 10:1, and 20:1, respectively. After 4 days of co-culture, cells were harvested, and CD8⁺ T cell proliferation was assessed by flow cytometric analysis of CFSE dilution. Statistical Analysis Data are presented as the mean ± standard deviation. Unpaired Student’s t-test or one-way analysis was performed for statistical analysis using GraphPad Prism 7 (GraphPad Software, Inc.). All experiments were independently repeated at least three times. Numerical data are shown as means ± standard error of the mean (SEM). Throughout all figures: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Significance was concluded at p < 0.05. Results SYK Activation Causes Spontaneous Rheumatoid Arthritis and Increases Global DCs We had previously observed that gain-of-function variants of SYK lead to spontaneous RA in humans and mice [19]. To further investigate the role of SYK in the progression of RA, we sought to use the SYK gain-of-function mouse model (SYKS544Y) built by our team using a CRISPR-Cas9 approach. In alignment with prior research, the SYKS544Y mice exhibited severe spontaneous rheumatoid arthritis at the age of three months, as indicated by pronounced hind-paw and fore-paw swelling (Fig. S1a), and a markedly increased arthritis clinical score (Fig. S1b), whereas none of those phenotypes was observed in WT controls. Micro-computed tomography (micro-CT) analysis of ankles further demonstrated that SYKS544Y mice exhibited severe bone erosion compared to WT controls (Fig. S1c). Additionally, histologic inspection of ankle sections revealed pronounced signs of bone erosion and extensive infiltration of immune cells (Fig. 1a). Collectively, these findings underscore a pivotal role for SYK activation-mediated immune cell infiltration in the pathogenesis of RA. Fig. 1SYK activation causes spontaneous rheumatoid arthritis and increases global DCs. (a) Photographs of the hind limb and fore limb of WT and SYKS544Y mice at the age of 3 months (n = 5). (b) Quantification of arthritis severity by clinical score at the age of 3 months (n = 5). (c) Representative micro-CT images of the ankle joints of WT and SYKS544Y mice at the age of 3 months (n = 5). (d) Normalized counts of CD3+ T cells, B220+ B cells, CD11B+LY6G+ neutrophils, CD11B+LY6C+ monocytes, CD11C+MHCII+ DCs of total CD45+ blood lymphocytes from WT or SYKS544Y mice (n ≥ 3). (e) Normalized counts of CD3+ T cells, B220+ B cells, CD11B+LY6G+ neutrophils, CD11B+LY6C+ monocytes, CD11C+MHCII+ DCs of total CD45+ spleen lymphocytes from WT or SYKS544Y mice (n ≥ 3). (f) Normalized counts of CD3+ T cells, B220+ B cells, CD11B+LY6G+ neutrophils, CD11B+LY6C+ monocytes, CD11B+LY6C+CCR2+monocytes, CD11B+F4/80+ macrophage, CD11C+MHCII+ DCs. of total live cells from WT or SYKS544Y mice ankles (n ≥ 3). In all panels, **p < 0.01. A p-value less than 0.05 was considered significant SYK activation causes spontaneous rheumatoid arthritis and increases global DCs. (a) Photographs of the hind limb and fore limb of WT and SYKS544Y mice at the age of 3 months (n = 5). (b) Quantification of arthritis severity by clinical score at the age of 3 months (n = 5). (c) Representative micro-CT images of the ankle joints of WT and SYKS544Y mice at the age of 3 months (n = 5). (d) Normalized counts of CD3+ T cells, B220+ B cells, CD11B+LY6G+ neutrophils, CD11B+LY6C+ monocytes, CD11C+MHCII+ DCs of total CD45+ blood lymphocytes from WT or SYKS544Y mice (n ≥ 3). (e) Normalized counts of CD3+ T cells, B220+ B cells, CD11B+LY6G+ neutrophils, CD11B+LY6C+ monocytes, CD11C+MHCII+ DCs of total CD45+ spleen lymphocytes from WT or SYKS544Y mice (n ≥ 3). (f) Normalized counts of CD3+ T cells, B220+ B cells, CD11B+LY6G+ neutrophils, CD11B+LY6C+ monocytes, CD11B+LY6C+CCR2+monocytes, CD11B+F4/80+ macrophage, CD11C+MHCII+ DCs. of total live cells from WT or SYKS544Y mice ankles (n ≥ 3). In all panels, **p < 0.01. A p-value less than 0.05 was considered significant To elucidate the effects of SYK activation on immune cell populations, we initially assessed the frequencies of CD3+ T cells, B220+ B cells, CD11B+LY6G+ neutrophils, CD11B+LY6C+ monocytes, and CD11C+MHCII+ DCs in the blood using flow cytometry analysis (FACS). Consistent with previous studies [19], we observed a significant increase of T cells (~ 100%) and a decrease of B cells (~ 50%), while neutrophil frequency did not show significant differences. Notably, the frequency of monocytes was greatly increased, and the number of DCs (CD11C+MHCII+) in SYKS544Y mice was ~ 3.3-fold higher compared to WT controls (Fig. 1b and Fig. S1d). The alterations in the frequencies of T and B cells, neutrophils, monocytes, and DCs in the spleen were consistent with those observed in the blood (Fig. 1c and Fig. S1e). Subsequently, we analyzed the cellular composition in ankles. The frequency of CD45⁺ cells in SYKS544Y mice was 47% higher than that in WT controls (Fig. 1d and Fig. S1f), indicating that SYK activation promotes the infiltration of immune cells into ankles. Meanwhile, B cell frequencies decreased by 69% (Fig. 1d and Fig. S1f), while T cells, neutrophils, monocytes, macrophages and DCs all showed increased frequencies in the inflamed ankles of SYKS544Y mice (78% increase in T cells, 144% increase in neutrophils, 46% increase in monocytes, 97% increase in macrophages, and 189% increase in DCs) (Fig. 1d and Fig. S1f). Interestingly, we also found an increase of CD11B+LY6C+CCR2+ inflammatory monocytes in the ankle of SYK mice (4.8% in SYKS544Y vs. 2.9% CD11C+ area in WT mice) (Fig. 1d and Fig. S1f). As DCs can be derived from monocytes [21], we hypothesized that SYK activation-mediated DC expansion may be dependent on monocytes. To further confirm the expansion of DCs, we performed immunohistochemistry. A substantial increase in CD11C+ cells was detected in the spleens of SYK mice (16.0% CD11C+ area in SYKS544Y vs. 7.6% CD11C + area in WT mice) (Fig. 1e). Moreover, in ankles, the proportion of CD11C+ cell area in SYKS544Y mice was 11.9%, which was much higher than the 0.4% observed in the WT controls (Fig. 1f). Given that DCs in rheumatoid arthritis (RA) serve as antigen-presenting cells with a high capacity for T-cell stimulation [22, 23], and an enhanced ability to recruit neutrophils [24], we hypothesized that SYK activation may promote the maturation of DCs, thereby increasing the number of T cells and neutrophils in ankles. Indeed, FACS analysis revealed a 163% increase in the frequency of mature CD11C⁺CD40⁺ DCs (Fig. 1g) and a 260% increase in the frequency of CD11C⁺CD86⁺ DCs (Fig. 1h) in SYKS544Y mice compared to WT controls. These findings suggest that SYK may facilitate the infiltration of T cells and neutrophils into the joints by promoting the maturation of DCs. SYK Activation Promotes pDC and cDC2 Infiltration in the Ankle Flow cytometry analysis and single-cell RNA sequencing have delineated three major DC subsets within the synovia of RA patients, namely plasmacytoid DCs (pDCs) and conventional DCs (cDCs) [25]. pDCs, characterized by high-level expression of B220 LY6C, and CD304, play a pivotal role in defending against viral infections through the production of type I interferons [26–29]. cDCs can be further categorized into cDC1 and cDC2. cDC1, predominantly expressing CD141, CD8a, and CD103, are capable of activating CD8⁺ T cells via cross-presentation through MHC class I [30]. cDC2 represents the predominant subtype of cDCs, exhibiting high expression of CD11B and CD1C, as well as antigen-presenting and co-stimulatory molecules [31]. To explore which DC subtypes are affected by SYK activation, we conducted FACS of blood, spleen and ankle based on the surface markers of DCs. Compared with the WT group, the frequency of CD11C+B220+LY6C+ pDCs was ~ 4.1-fold in the ankle of SYKS544Y mice (Fig. 2a). However, no significant differences in the number of pDCs were observed in the blood and spleen among WT and SYKS544Y mice (Fig. 2b and c). This disparity was likely due to the decrease of B220+ B cells in SYKS544Y mice. CD304 is another well-known pDC marker [29]. We further analyzed the frequencies of CD11C+MHCII+CD304+ pDC, and found a significant increase of this pDC in the blood, spleen, and ankle of SYKS544Y mice (Fig. 2 d and f). Meanwhile, in the ankles of SYKS544Y mice, an increase in CD11C⁺MHCII⁺CD11B⁺CD8a⁻ cDC2 was observed (Fig. 2 g and i). Interestingly, there was no obvious CD11C+MHCII+CD11B−CD8a+ cDC1 subtypes in the ankle (Fig. 2i). The cDC2 subtypes also showed an increase in the blood and spleen of SYKS544Y mice (Fig. 2j and k). These findings suggested that the gain-of-function of SYK promotes the infiltration of both pDC and cDC2 into the ankles. Fig. 2SYK promotes pDC and cDC2 infiltration in the ankle. (a-c) Frequencies and normalized counts of CD11C+B220+LY6C+ plasmacytoid DCs in the ankle (a), blood (b) and spleen (c) of WT and SYKS544Y mice (n = 3). (d-f) Frequencies and normalized counts of CD11C+MHCII+CD304+ plasmacytoid DCs in the ankle (d), blood (e) and spleen (f) of WT and SYKS544Y mice (n = 3). (g) Gating strategy of conventional DCs(cDC). (h) Percentage of CD11C+MHCII+CD11B+CD8a− cDC2 in the ankle of WT and SYKS544Y mice (n = 4). (i) Representative plots show CD11C+MHCII+CD11B+CD8a− cDC2 populations (n = 4). (j-k) Percentage of CD11C+MHCII+CD11B+ CD8a− cDC2 in the blood (j) and spleen (k) of WT and SYKS544Y mice (n = 4). In all panels, NS was not significant, **p < 0.01, ****p < 0.0001. A p-value less than 0.05 was considered significant SYK promotes pDC and cDC2 infiltration in the ankle. (a-c) Frequencies and normalized counts of CD11C+B220+LY6C+ plasmacytoid DCs in the ankle (a), blood (b) and spleen (c) of WT and SYKS544Y mice (n = 3). (d-f) Frequencies and normalized counts of CD11C+MHCII+CD304+ plasmacytoid DCs in the ankle (d), blood (e) and spleen (f) of WT and SYKS544Y mice (n = 3). (g) Gating strategy of conventional DCs(cDC). (h) Percentage of CD11C+MHCII+CD11B+CD8a− cDC2 in the ankle of WT and SYKS544Y mice (n = 4). (i) Representative plots show CD11C+MHCII+CD11B+CD8a− cDC2 populations (n = 4). (j-k) Percentage of CD11C+MHCII+CD11B+ CD8a− cDC2 in the blood (j) and spleen (k) of WT and SYKS544Y mice (n = 4). In all panels, NS was not significant, **p < 0.01, ****p < 0.0001. A p-value less than 0.05 was considered significant SYK Activation Promotes DC proliferation, maturation, and Endocytosis To gain insight into the impact of SYK activation on DC functions, we conducted a comprehensive series of in vitro functional assays, including proliferation, maturation, and endocytosis tests, using bone marrow-derived dendritic cells (BMDCs) in vitro. BMDCs from SYKS544Y mice showed increased phosphorylated-SYK (Tyr 525/526) and activation of downstream signaling, such as Jnk and Erk1/2, which can be inhibited by R406 (SYK inhibitor) treatment (Fig. 3a). These results indicate that the SYKS544Y mutation leads to the activation of SYK signaling pathways. The MTS assay revealed that BMDCs from SYKS544Y mice demonstrated a stronger proliferative capacity compared to those from WT mice (Fig. 3b). FACS further confirmed that the expression levels of CD11C and co-stimulatory molecules, including CD40, CD86, and MHCII, were elevated in BMDCs from SYKS544Y mice (Fig. 3c and d). Subsequently, we employed a dextran uptake assay to determine the endocytic capacity of DC. The endocytosis of mature or immature BMDC from SYKS544Y mice was found to be increased at both 4℃ and 37℃ (Fig. 3e and h). Based on these observations, we hypothesized that BMDCs from SYKS544Y mice might possess a greater potential to promote T-cell proliferation. To validate this hypothesis, we performed an in vitro co-culture assay of DCs and T cells. Carboxyfluorescein diacetate Succinimidyl Ester (CFSE)-labeled OT-1 CD8+ T cells were co-cultured with either WT or SYKS544Y BMDCs at various ratios. The results demonstrated that SYKS544Y BMDCs were more effective in promoting the proliferation of OT-1 CD8⁺ T cells compared to WT BMDCs at both 20:1 and 10:1 ratios (Fig. 3i and j). Furthermore, flow cytometry analysis also showed increased p-SYK in SYKS544Y BMDCs after DC-T cell interaction compared with that of WT controls (Fig. 3k), which provides evidence that the SYKS544Y mutation with high p-SYK expression may be associated with stronger T cell-promotion activity. Together, these data suggested that SYK activation enhances BMDC proliferation, maturation, endocytosis, and T cell-promotion activity. Discussion The expansion and accumulation of DCs in the ankle constitute a prominent feature in the pathogenesis of RA. Targeting DCs is thus considered an urgent need to enhance therapeutic outcomes for RA patients [32]. Consequently, a profound understanding of the mechanisms governing DC functions is pivotal for the development of innovative treatment strategies for RA. In this study, we have identified SYK as a key mediator of DC functions in RA. Our findings reveal that gain-of-function mutation of SYK in mice induces the infiltration of DCs, especially CD11C+B220+LY6C+ pDCs and CD11C+MHCII+CD11B+CD8a− cDC2 subtype into the ankle joint. Furthermore, bone marrow-derived DCs (BMDCs) from SYKS544Y mutant mice exhibit heightened maturation and phagocytic activity, which subsequently enhances their capacity to promote T cell proliferation. Collectively, these observations underscore the crucial role of SYK activation-mediated enhancement of DC functions in the pathology of RA. Fig. 3SYK enhances DC functions. (a) Western blot analysis of WT and SYKS544Y BMDC SYK phosphorylation (Tyr525/526), total SYK expression, JNK1 (T183/Y185) phosphorylation, total JNK1 expression, ERK1 phosphorylation (T203/Y205) and total ERK1 expression treated or not treated with R406 SYK inhibitor. (n = 3) (b) MTS test of WT and SYKS544Y BMDCs in 24 and 48 h (n = 3). (c) Percentage of CD11C+ cells in BMDC derived from WT and SYKS544Y mice (n ≥ 5). (d) Percentage of CD40+, CD86+, MHCII+ cells of total CD11C+ in BMDC derived from WT and SYKS544Y mice (n ≥ 5). (e-f) Percentage and representative plots of mature FITC+ BMDCs incubated at 4℃ (f) and 37 ℃ (g) for 1 h. (n = 5). (g-h) Percentage and representative plots of immature FITC+ BMDCs incubated in 4℃ (f) and 37 ℃ (g) for 1 h (n = 5). (i) Proliferation of OT-II CD8 T cells cocultured with WT or SYKS544Y BMDCs in various ratios (n = 3). (j) Representative plots show the proportion of proliferative CD8 T cells cocultured with WT or SYKS544Y BMDCs in 20:1, 10:1, and 5:1 ratios. (k) p-SYK expression in WT and SYKS544Y BMDCs after DC-T cell interaction by FACS (n = 5). In all panels, NS was not significant, **p < 0.01, ***p < 0.001 and ****p < 0.0001. A p-value less than 0.05 was considered significant SYK enhances DC functions. (a) Western blot analysis of WT and SYKS544Y BMDC SYK phosphorylation (Tyr525/526), total SYK expression, JNK1 (T183/Y185) phosphorylation, total JNK1 expression, ERK1 phosphorylation (T203/Y205) and total ERK1 expression treated or not treated with R406 SYK inhibitor. (n = 3) (b) MTS test of WT and SYKS544Y BMDCs in 24 and 48 h (n = 3). (c) Percentage of CD11C+ cells in BMDC derived from WT and SYKS544Y mice (n ≥ 5). (d) Percentage of CD40+, CD86+, MHCII+ cells of total CD11C+ in BMDC derived from WT and SYKS544Y mice (n ≥ 5). (e-f) Percentage and representative plots of mature FITC+ BMDCs incubated at 4℃ (f) and 37 ℃ (g) for 1 h. (n = 5). (g-h) Percentage and representative plots of immature FITC+ BMDCs incubated in 4℃ (f) and 37 ℃ (g) for 1 h (n = 5). (i) Proliferation of OT-II CD8 T cells cocultured with WT or SYKS544Y BMDCs in various ratios (n = 3). (j) Representative plots show the proportion of proliferative CD8 T cells cocultured with WT or SYKS544Y BMDCs in 20:1, 10:1, and 5:1 ratios. (k) p-SYK expression in WT and SYKS544Y BMDCs after DC-T cell interaction by FACS (n = 5). In all panels, NS was not significant, **p < 0.01, ***p < 0.001 and ****p < 0.0001. A p-value less than 0.05 was considered significant SYK is a critical molecule downstream of the immune cell receptor signaling pathway, playing a crucial role in a diverse array of biological processes, including hematopoietic malignancies, inflammation, and autoimmune diseases. The involvement of SYK in the development and progression of RA has been well-documented. Syk is expressed in the synovium of RA patients, and notably, the expression of phospho-Syk (pSYK) is significantly elevated in both the synovial tissue and peripheral blood B cells of RA patients when compared to those with osteoarthritis [33, 34]. Moreover, studies using hematopoietic bone marrow chimeras deficient in Syk have demonstrated complete protection against autoantibody-mediated RA [13]. This underscores the significance of SYK in the pathogenesis of RA. Additionally, inhibiting SYK with compounds such as R406 or R788 has been shown to suppress RA disease activity effectively. However, these inhibitors are associated with certain side effects, including diarrhea, hypertension, and neutropenia, which may be attributed to the widespread expression of SYK across various cell types [14, 16, 17]. Therefore, the critical immune cell types that SYK signaling may affect need to be fully elucidated in the pathogenesis of RA. Several studies have shown that SYK is involved in various immune cell receptor signaling, including T, B cells, osteoclasts, macrophages, and neutrophils. A meticulous investigation involving lineage-specific deletion of Syk in neutrophils, platelets, and mast cells has provided compelling evidence that Syk expression in neutrophils is of paramount importance in autoantibody-induced arthritis [35]. Moreover, a 3-arylbenzofuran derivative named EIE-2 has shown promise as a potential therapeutic agent. It is believed to target Syk, thereby restoring the homeostasis of regulatory T cells (T-regs). This action has been demonstrated to alleviate symptoms and mitigate pathological damage in both rat and mouse models of RA [36]. Our previous study revealed that gain-of-function in SYK leads to the development of RA in humans and mice. We observed increased osteoclasts in the inflamed joints of SYKS544Y mice, and bone marrow-derived macrophages of SYKS544Y mice can differentiate into more osteoclasts in vitro compared to WT mice [19]. As we showed in this study, SYK activation significantly increased the abundance of peripheral and ankle-infiltrating DCs, and enhanced DCs potential to promote T cell proliferation mainly through upregulation of costimulatory molecules MHCII, CD40, and CD86, which highlighted a crucial role in RA pathogenesis of the SYK-DC axis. Consistent with our findings, a study by Andrew M. Platt and colleagues showed that SYK inhibition by fostamatinib abrogates T cell-priming capacity of DCs by reducing expression of co-stimulatory molecules [37]. We also find a significant increase of CD11B+LY6C+ monocytes in the blood, spleen and ankle, indicating that SYK activation mediated DC expansion may be dependent on monocytes, which requires further exploration. As DC-T cell crosstalk is crucial for inducing RA and maintaining immune tolerance, targeting DC-T cell crosstalk may become a future direction to delay RA development and progression [38]. Our study indicated that the SYK-DC-T axis may be a promising therapeutic target for RA treatment. Overall, our results revealed that SYK activation enhanced the maturation and infiltration of dendritic cells (DCs) in the ankle joint, which is critical for RA pathogenesis. Our findings may lead to the development of SYK or its downstream DCs as therapeutic options. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 474 KB) Supplementary file1 (DOCX 474 KB)